Hedge fund Matrix Capital Management led a $100 million Series B round for Palleon Pharmaceuticals, a leader in the emerging field of glycobiology.
The funding will help . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.